Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2009
10/28/2009CN100553678C Novel albumin-free factor VIII formulations
10/28/2009CN100553675C Process of preparing calcitonin microsphere
10/28/2009CN100553674C Medicinal composition of recombinant human parathormone(1-84) and its preparing process
10/28/2009CN100553639C Boronic acid polyvalent salts for treating thrombosis
10/28/2009CN100553637C Hormone composition
10/27/2009US7610289 System and method for monitoring and analyzing internet traffic
10/27/2009US7608701 Corticotropin releasing factor 2 receptor agonists
10/27/2009US7608698 Muscular disorders; cardiovascular disorders; cell transformed with nucleic acid; culture product
10/27/2009US7608697 Mixture comprising enzymatic polypeptides with proline modified terminal for use in enhancing/reducing digestion/flavor/bitterness of foods; food processing
10/27/2009US7608696 Immunoglobulin for use in diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions; drug screening; immunotherapy and diagnostics; anticarcinogenic agents
10/27/2009US7608692 or exendin-4 agonists covalently bonded to albumin, polyethylene glycol, gelatin, (hydroxypropyl)-methacrylamide, a polyamino acid, fatty acid, polysaccharide, dextran to increase molecular size; diabetes, postprandial dumping syndrome, postprandial hyperglycemia, dyslipidemia, obesity; renal filtration
10/27/2009US7608691 Antibodies against IL-16 antagonist peptides
10/27/2009US7608690 IL-B30 antibodies
10/27/2009US7608687 Releasable linkage and compositions containing same
10/27/2009US7608686 Ztnfr12 polypeptides and Ztnfr12 fusion proteins
10/27/2009US7608685 Tumor antigen based on products of the tumor suppressor gene WT1
10/27/2009US7608684 Soluble CD14 antigen
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608681 Methods and compositions for prolonging elimination half-times of bioactive compounds
10/27/2009US7608632 Sulfonamide inhibitors of aspartyl protease
10/27/2009US7608602 Beta -1-(4-Allyloxycarbonylamino-2-oxo-1H-pyrimidin-1-yl)-2-deoxy-2,2-difluororibose, for example; for treating or preventing diseases or disorders such as cancer or viral infections
10/27/2009US7608592 HCV inhibitors
10/27/2009US7608591 Targeted delivery to legumain-expressing cells
10/27/2009US7608590 19-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2, 16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-4,14-dicarboxylic acid 4-ethyl ester 14-methyl ester, for example; inhibits the NS3 protease of flavivirus such as hepatitis C virus (HCV)
10/27/2009US7608589 Peptidyl diacylglycerides
10/27/2009US7608588 Methods of increasing bone density/preventing osteoporosis, of reducing joint pain and/or joint deterioration from osteoarthritis, degenerative joint disease, joint defect, and rheumatoid arthritis; maximum and consistent bioavailability
10/27/2009US7608587 Exendin 4 polypeptide fragment
10/27/2009US7608586 Binding may be used to detect A beta or to separate A beta from the rest of a subject's body; in Alzheimer's disease, it may be used to provide diagnostic results by detecting A beta , treatment by removing A beta , or both
10/27/2009US7608585 Brain-derived neurotrophic factor (BDNF) and antioxidant Neu 2000 which is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino)benzoic acid; synergistic; neuroprotectant
10/27/2009US7608583 Expressing the insulin in yeast, wherein the expressed insulin is secreted into the culture medium, adding water miscible organic solvent to fermentation culture broth containing secreted insulin and yeast, clarifying fermentation culture broth by centrifugation and decanting supernatant from the pellet
10/27/2009US7608580 Osteogenic protein such as Bone Morphogenic Protein, hyaluronic acid derivatives and porogen or sodium bicarbonate; bone repair, or tendon, cartilage repair; allows for closed fracture repair
10/27/2009US7608579 Lung volume reduction using glue compositions
10/27/2009US7608578 Injecting a biocompatible bulking material such as collagen, elastin or fibrin submucosally or intramuscularly into pyloric area of the stomach to cause the lumen of pylorus to narrow and slow gastric emptying
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608445 Increased activity and stability at increased pH and temperature
10/27/2009US7608428 Polynucleotide encoding an IL-28B polypeptide
10/27/2009US7608427 Encoding polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity
10/27/2009US7608411 Prostaglandin receptor EP1
10/27/2009US7608409 Screening assay using G-protein coupled receptor protein OT7T175
10/27/2009US7608401 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608283 Coral purification method and coral thus obtained
10/27/2009US7608281 Retinoic acid receptors (RAR); tissue engineering, cartilage formation; for treatment of cartilage degenerative disease, skeletal trauma; bone morphogenetic protein (BMP), osteogenic protein (OP)
10/27/2009US7608280 Method of producing FR901228
10/27/2009US7608276 vaccines, immunogenic compositions; diagnostics, enzymatic studies and targets for antibiotics; for treating Staphylococcus aureus infection
10/27/2009US7608274 Therapeutic processes and useful compositions therefor
10/27/2009US7608271 Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
10/27/2009US7608269 Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
10/27/2009US7608268 Ferritin fusion proteins for use in vaccines and other applications
10/27/2009US7608267 Fusion protein of two different cytokines, one capable of enhancing a nonspecific immune response, and the other capable of enhancing a specific immunity; fusion protein of Interleukin-2 (Il-2) and IL-7 for example; use in immunotherapy such as cancer vaccine
10/27/2009US7608264 Monoclonal antibody or antibody fragment which binds a pleiotrophin-binding fragment of human Anaplastic Lymphoma Kinase (ALK) and inhibits a pleiotrophin-mediated activity; prevents pleiotrophin-mediated neoplastic or mitogenic activity
10/27/2009US7608262 Such as antibodies; treating acute mycocardial infarction, deep vein thrombosis, stroke and thrombophlebitis
10/27/2009US7608261 VEGF antagonist formulations suitable for intravitreal administration
10/27/2009US7608257 Using a reovirus and chemotherapeutic agents to treat ras-activated neoplastic cells; proliferative disorders
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009US7608243 RGD peptide sequence; labelled with fluorescein used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases; peptidic vector and the fluorescein dye are coupled; cyclic peptide forming disulife or monothioether bridge
10/27/2009CA2430318C Powder formulation and method for producing the same
10/27/2009CA2413798C Needle for intradermal delivery of substances having penetration limiting means
10/27/2009CA2341434C Pyrrolobenzodiazepine compounds
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2328904C Novel (poly)peptides which represent the epitopes of the human herpesvirus type 8
10/27/2009CA2288184C Method for treating a lactic raw material containing gmp
10/27/2009CA2224143C Recombinant hexose oxidase, a method of producing same and use of such enzyme
10/27/2009CA2162366C Conjugation-stabilized polypeptide compositions
10/26/2009WO2006111524A2 Il-21 variants
10/24/2009CA2665510A1 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines
10/22/2009WO2009129502A2 Immunotherapies employing self-assembling vaccines
10/22/2009WO2009129498A2 Substance p and analogs thereof as a cancer immunogenic composition adjuvant
10/22/2009WO2009129408A2 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/22/2009WO2009129379A1 Methods for enhanced production of bone morphogenetic proteins
10/22/2009WO2009129374A2 Methods and compositions for preventing adhesion
10/22/2009WO2009129250A2 Meal-time insulin analogues of enhanced stability
10/22/2009WO2009129220A2 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
10/22/2009WO2009129205A2 Sparc anti-inflammatory activity and uses thereof
10/22/2009WO2009129164A1 Pharmaceutical combinations of tfpi-fragments and an antibiotic
10/22/2009WO2009129120A2 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
10/22/2009WO2009129101A1 Liquid buffered gdf-5 formulations
10/22/2009WO2009128952A2 Compositions of papillomavirus proteins and methods of use
10/22/2009WO2009128936A2 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
10/22/2009WO2009128918A1 Combination therapy using a soluble hyaluronidase and a bisphosphonate
10/22/2009WO2009128917A2 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
10/22/2009WO2009128772A1 Stable amyloid beta monomers and oligomers
10/22/2009WO2009128713A1 Egg protein hydrolysates
10/22/2009WO2009128584A1 The composition for the prevention and treatment of striae distensae and atopy
10/22/2009WO2009128523A1 Immunostimulating agent
10/22/2009WO2009128489A1 Tablet containing vancomycin hydrochloride
10/22/2009WO2009128474A1 Method of producing thrombin-immobilized bioabsorbable sheet preparation
10/22/2009WO2009128446A1 Ameliorating agent for neurogenic pain
10/22/2009WO2009128360A1 Therapeutic agent for diabetes
10/22/2009WO2009128357A1 Bioactive protein-containing nanoparticle composition and method for producing the same
10/22/2009WO2009128077A1 Stable cell binding chimeric peptides
10/22/2009WO2009128070A1 Agents and methods for treatment of anxiety disorders
10/22/2009WO2009127940A1 Osteogenic composition including a complex growth factor/amphiphilic polymer, a soluble cation salt, and an organic substrate
10/22/2009WO2009127939A1 Osteogenic composition including growth factor, soluble cation salt, and organic substrate
10/22/2009WO2009127826A1 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
10/22/2009WO2009127768A1 Use of liver growth factor (lgf) as a neural tissue regenerator
10/22/2009WO2009127754A1 USE OF eNOS INHIBITORS IN NERVOUS REGENERATION
10/22/2009WO2009127705A1 Novel therapeutical tools and methods for treating blindness
10/22/2009WO2009127249A1 Method for identifying compounds suitable for stimulation of stem cell production in skin
10/22/2009WO2009127140A1 7p peptide and its derivant, the use thereof
1 ... 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 ... 3163